Related Scientific Publications

07.12.2022 / Efficacy and safety of COVID‐19 vaccines (Cochrane Library): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015477/epdf/full

11.2022 / Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination (Journal of Immunological Methods): https://www.sciencedirect.com/science/article/pii/S0022175922001326?via%3Dihub

10.2022 / Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey (Journal of Infection and Public Health): https://www.sciencedirect.com/science/article/pii/S1876034122002118?via%3Dihub

08.10.2022 / A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network (Trials): https://pubmed.ncbi.nlm.nih.gov/36209129/

19.09.2022 / Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey (Enfermedades Infecciosas y Microbiología Clínica): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534071/

31.08.2022 / Vaccination rates in Europe are not associated with online media intensity (JCOM Journal of Science Communication): https://jcom.sissa.it/archive/21/05/JCOM_2105_2022_A05

18.06.2022 / A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022 (Infection): https://link.springer.com/article/10.1007/s15010-022-01931-7

02.06.2022 / VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment (Vaccine): https://www.sciencedirect.com/science/article/pii/S0264410X22006053?via%3Dihub

11.01.2022 / Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library): https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000065/full

29.07.2021 / Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 (The Lancet Infectious Diseases): https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00420-5/fulltext

27.05.2021 / Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) (The Lancet): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233007/